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Long-Term Effectiveness and Safety of Sirolimus
Stent Implantation for Coronary In-Stent Restenosis
Results of the TRUE (Tuscany Registry of Sirolimus
for Unselected In-Stent Restenosis) Registry at 4 Years
Francesco Liistro, MD,* Massimo Fineschi, MD,† Simone Grotti, MD,* Paolo Angioli, MD,*
Arcangelo Carrera, MD,† Kenneth Ducci, MD,* Tommaso Gori, MD,† Giovanni Falsini, MD,*
Carlo Pierli, MD,† Leonardo Bolognese, MD*
Arezzo and Siena, Italy
Objectives The aim of this study was to evaluate the long-term clinical outcome of the efficacy and safety of sirolimus-
eluting stents (SES) for in-stent restenosis (ISR) in the TRUE (Tuscany Registry of Unselected In-Stent Restenosis)
database.
Background The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target
lesion revascularization [TLR]) and safe (stent thrombosis 1%) at 9 months. Clinical outcome at 4 years is
reported.
Methods A total of 244 patients with ISR who were treated with SES implantation represent the study population. The
incidence of major adverse cardiac events was collected at 4 years.
Results At 4-year follow-up, overall mortality was 9.8% (24 patients). Cardiac death occurred in 11 (4.5%), nonfatal myo-
cardial infarction in 8 (3.2%), and TLR in 27 (11.1%) patients for a cumulative event-free survival rate of 80.3%.
Definite stent thrombosis occurred in 5 (2%) patients and possible stent thrombosis in 2 (0.8%). Diabetes re-
mained an independent negative predictor of freedom from TLR (odds ratio [OR]: 0.38; 95% confidence interval
[CI]: 0.20 to 0.71, p  0.002) and major adverse cardiac events (OR: 0.38; 95% CI: 0.20 to 0.71, p  0.002).
Conclusions The clinical benefit of SES implantation for bare-metal stent ISR is maintained at 4 years with a low TLR rate
and an overall incidence of stent thrombosis of 0.7% per year. (J Am Coll Cardiol 2010;55:613–6) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.075w
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She superiority of drug-eluting stents (DES) compared
ith balloon angioplasty and vascular brachytherapy for
he treatment of patients with in-stent restenosis (ISR)
as been shown in observational and randomized trials
1– 4). However, because both DES and brachytherapy
imilarly share inhibition of late loss as the mechanism of
enefit, a long-term follow-up is needed to show whether
he benefit is diluted over years. Furthermore, the advent
f DES has raised concerns regarding later occurrence of
tent thrombosis beyond the traditional 9-month time
rame (5– 8), especially in complex lesion subsets, such as
atients with ISR. No data are currently available on the
afety/benefit profile of DES in this subset of patients at
ong-term follow-up. Thus, we sought to investigate
rom the *Cardiovascular Department, San Donato Hospital, Arezzo, Italy; and
Cardiovascular Department, Le Scotte Hospital, Siena, Italy.f
Manuscript received June 26, 2009; revised manuscript received August 24, 2009,
ccepted August 24, 2009.hether the midterm clinical benefit of DES implanta-
ion for bare-metal stent (BMS) ISR observed in the
RUE (Tuscany Registry of Unselected In-Stent Reste-
osis) (9) database was maintained long-term (4 years).
ethods
he design of the registry has been previously reported
9). Briefly, the study was designed as a prospective,
ingle-arm, 2-center registry to evaluate clinical outcome
fter the implantation of a sirolimus-eluting stent (SES)
or the treatment of ISR. Combined antiplatelet therapy
ith aspirin (at least 100 mg daily) and ticlopidine 500
g daily (or clopidogrel 75 mg daily) was started at least
8 h before the procedure and continued for at least 6
onths.
tudy population and definitions. Two hundred forty-
our consecutive patients treated with SES implantation
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SES for In-Stent Restenosis February 16, 2010:613–6for BMS restenosis were fol-
lowed up until 4 years after
study entry.
Bifurcation restenotic lesions
were defined as a restenosis50%
in both the main branch and the
ostium of the side branch. Major
adverse cardiac events (MACE)
were defined as death from any
cause, nonfatal reinfarction, and
ischemia-driven target lesion re-
vascularization (IDTLR). Myo-
cardial infarction was defined as
the presence of new Q waves in
2 contiguous electrocardio-
gram leads or an elevation of
creatine kinase or its myocar-
dial band isoenzyme to 3
imes the upper limit of normal in 2 samples during
ospitalization or to 2 times the upper limit of normal
fter discharge. IDTLR was defined as any repeat revas-
ularization due to lumen renarrowing within the stent or
n the 5-mm distal or proximal segments associated with
ymptoms or objective signs of ischemia. Stent thrombo-
is (ST) was defined according to the Academic Research
onsortium classification (10).
tatistical analysis. Values are reported as numbers with
elative percentage or SD. Kaplan-Meier analysis was
sed to assess survival free from MACE and survival free
rom IDTLR alone. Cox regression analysis was used to
dentify independent predictors of MACE and IDTLR
lone. Odds ratio (OR) and 95% confidence intervals
CIs) were reported with 2-tailed probability value. A value
f p  0.05 was considered statistically significant. All
tatistical computations were performed by StatView ver-
ion 6 (SAS Institute, Cary, North Carolina) procedures.
esults
aseline clinical and procedural variables of the patients
ere previously reported in detail (9). Twenty-three
atients presented with a restenosis at the bifurcation site
distal left main in 3 patients, left anterior descending
rtery in 12 patients, circumflex in 8 patients) involving a
MS in the main branch while the ostium of the side
ranch was not primarily stented. All these bifurcation
estenoses were treated with SES implantation in the main
ranch and a balloon dilation in the side branch.
Clinical outcome at 1 year, between 1 and 4 years
ollow-up, as well as for the entire study period is reported
n the Table 1.
A follow-up period of 4 years was achieved in all
atients. Beyond the 1-year time frame (Table 1), we
bserved 31 new MACE episodes: 20 additional patients
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
IDTLR  ischemia-driven
target lesion revascularization
ISR  in-stent restenosis
MACE  major adverse
cardiac events
OR  odds ratio
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularizationied (7 from cancer, 2 from renal failure, 2 from stroke, pduring surgical limb revascularization, 4 from heart
ailure, 1 perioperatively for coronary artery bypass graft,
from fatal infarction, 1 from sudden death), 4 patients
ad a nonfatal infarction, and 14 patients had IDTLR.
verall, during the entire study period, death occurred in
4 patients (10%) (31  19 months from the procedure,
ean age 73  12 years). The cumulative incidence of
ACE was 20% (48 events) and of TLR was 11% (Fig.
). Cox regression model showed that diabetes (OR:
.38; 95% CI: 0.20 to 0.71, p  0.002), left ventricular
jection fraction 50% (OR: 0.32; 95% CI: 0.13 to 0.80,
 0.01), and creatinine 1.5 mg/dl (OR: 0.23; 95%
I: 0.11 to 0.48, p  0.0001) were independent predic-
ors of MACE. Diabetes (OR: 0.32; 95% CI: 0.14 to
.71, p  0.005) and peripheral or carotid arterial disease
OR: 0.35; 95% CI: 0.14 to 0.88, p  0.02) were
ndependent predictors of IDTLR alone. In patients with
iabetes, Kaplan-Meier estimation of freedom from
ACE is reported in Figure 2 and IDTLR alone in
igure 3.
Definite ST occurred in 5 (2%) patients (at 261, 614,
21, 631, and 847 days from the index procedure), and it
as fatal in 2 patients. Except for 1 patient who was on
spirin and clopidogrel at the time of the event, all patients
nterrupted clopidogrel more than 1 month before the
vent. There were 2 additional episodes of possible ST in
elderly patients (ages 85 and 89 years) treated for ISR
f the left main at 60 and 538 days from the index
rocedure, both on aspirin and clopidogrel at the time of
he event. Thus, the cumulative incidence of definite,
robable, or possible ST during the all-study period was
%, 0%, and 0.8% (Table 1). The mean duration of dual
ntiplatelet treatment (either clopidogrel or ticlopidine
nd aspirin) was 341  112 days. It was continued for 6
onths in 52 patients (21%), for 12 months in 168
linical Outcome at 4 YearsTable 1 Clinical Outcome at 4 Years
1 Year 4 Years Total
Death 4 (1.6) 20 (8.2) 24 (9.8)
Cardiac 3 (1.2) 8 (3.2) 11 (4.5)
Noncardiac 1 (0.4) 12 (4.9) 13 (5.3)
MI 5 (2) 6 (2.5) 11 (4.5)
Fatal 1 (0.4) 2 (0.8) 3 (1.2)
Nonfatal 4 (1.6) 4 (1.6) 8 (3.2)
Stent thrombosis 2 (0.8) 5 (2) 7 (2.8)
Definitive 1 (0.4) 4 (1.6) 5 (2)
Probable 0 0 0
Possible 1 (0.4) 1 (0.4) 2 (0.8)
IDTLR 13 (5.0) 14 (6.0) 27 (11.1)
PCI 12 (4.5) 11 (4.7) 23 (9.4)
CABG 1 (0.4) 3 (1.2) 4 (1.6)
Free from MACE 226 (93) 196 (80) 196 (80)
ata presented as n (%).
CABG  coronary artery bypass graft; IDTLR  ischemia-driven target lesion revascularization;
ACE  major adverse cardiac events; MI  myocardial infarction; PCI  percutaneous coronary
ntervention.atients (69%), and 24 months in 24 (10%) patients.
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February 16, 2010:613–6 SES for In-Stent Restenosisiscussion
everal registries as well as randomized clinical trials have
hown the superiority of DES over balloon angioplasty
nd vascular brachytherapy in the treatment of ISR
1– 4). However, the majority of these studies showed
fficacy and acceptable safety of DES over a limited
ollow-up period, and few data on long-term outcome are
vailable. In addition, after the pivotal reports describing
he occurrence of late ST after DES implantation,
onsistent findings have been echoed by several different
roups (5,7,11), raising a note of caution regarding the
afety/efficacy profile of this new coronary technology
Figure 1 Kaplan-Meier Survival
Curves in the Whole Study Group
Survival free from major adverse cardiac events (MACE) and
ischemia-driven target lesion revascularization (IDTLR) at 4-year follow-up.
Figure 2 Kaplan-Meier Event-Free
Survival Curves in Diabetic Population
Survival free from the combined end point of cardiac death, myocardial infarc-
tion, and IDTLR at 4-year follow-up in patients with and without diabetes.
Abbreviations as in Figure 1.mhen employed in unselected patient/lesion subsets such
s ISR. To our knowledge, this registry is the largest
eries of patients treated with SES for ISR lesions in a
eal-world scenario with no exclusion criteria concerning
atients’ clinical status as well as angiographic criteria
nd followed-up in a long-term format.
ajor findings of the study. 1) Clinical results at 4 years
onfirm the efficacy of SES in the prevention of IDTLR
ith an overall rate of 11% and the absence of late catch-up
bserved with brachytherapy or balloon angioplasty (12).
ur results compare favorably with those reported in the
ES arm of the SISR (Sirolimus-Eluting Stents Versus
ascular Brachytherapy for In-Stent Restenosis) trial (4)
TLR 17% at 3 years) and TAXUS V ISR (Paclitaxel-
luting Stents versus Brachytherapy for In-Stent Resteno-
is) trial (3) (TLR 10% at 2 years). However, the higher
umber of diabetic patients (33% in SISR, 40% in TAXUS
ISR vs. 26% in TRUE) and the different trial design
follow-up angiography in SISR) might explain the ob-
erved small differences in TLR rate. 2) We observed a
umulative incidence of ST of 2.8% (7 events; 0.70% per
ear) and a cumulative incidence of very late (1 year) ST
f 2% (5 events; 0.57% per year), as shown in other recent
egistries (6) and meta-analysis of the major randomized
ontrol trials related to DES implantation in de novo
oronary lesion (11). However, the adverse prognostic
nfluence of this event is also confirmed by our findings
50% mortality among patients exposed to the event), even
f the 2 sudden deaths accounted as ST occurred in very
lderly patients (age 85 years) and might be related to
ther causes. We did not find an excess of events after
hienopyridine discontinuation because most ST episodes
ccurred several months after the drug cessation. 3) Finally,
he higher rate of the combined end point of death,
Figure 3 Kaplan-Meier Survival Curves
for IDTLR in Diabetic Population
Survival free from IDTLR at 4-year follow-up in patients
with and without diabetes. Abbreviation as in Figure 1.yocardial infarction, and IDTLR and IDTLR alone
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SES for In-Stent Restenosis February 16, 2010:613–6bserved at 9-month follow-up in patients with diabetes
9,13) was confirmed long term.
tudy limitations. As a real-world registry, the study is
nherently limited by a lack of valid control groups using
istorical controls. However, one should also recognize that
any of the DES randomized trials performed for device
pproval have restricted enrollment criteria, making extrap-
lation of their findings to the greater population question-
ble (13).
The absence of a systematic late (12 months) control
oronary angiography did not allow a real estimation of the
ate catch-up phenomenon with DES in ISR lesions, which,
owever, seems to be clinically irrelevant. Finally, in patients
ith late occurrence of TLR, we could not exclude that the
tenotic lesion inside the stented segment represented a new
therosclerotic lesion instead of a restenosis.
onclusions
he midterm clinical benefit of SES implantation for BMS
SR is maintained over a long-term follow-up with a low
LR rate and an overall incidence of ST 1% per year.
eprint requests and correspondence: Dr. Francesco Liistro,
epartment of Cardiovascular Disease, San Donato Hospital, Via
eitro Nenni 22, 52100 Arezzo, Italy. E-mail: francescoliistro@
otmail.com.
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